Core IM | Internal Medicine Podcast
#144 RSV & What Makes Vaccine Trials Different: Beyond Journal Club on the RENOIR and AReSVi Trials
Jan 31, 2024
Join guest_name_1, an expert on RSV vaccines and vaccine trials, as they discuss the results of the RENOIR and AReSVi trials. Discover the challenges in creating an RSV vaccine and how to interpret vaccine trials. Explore the development of an RSV vaccine for older adults and the importance of considering patient's health status and risk factors when making vaccination recommendations.
23:28
AI Summary
AI Chapters
Episode notes
Podcast summary created with Snipd AI
Quick takeaways
- RSV vaccines demonstrate good efficacy, offering over 80% protection against severe RSV-related lower respiratory tract infections in adults over 60.
- Vaccine trials require careful consideration in terms of placebo selection, endpoints, and evaluating disease transmission for approval.
Deep dives
RSV vaccines provide protection against severe infections in older adults
The RSV and Renoir trials demonstrated that RSV vaccines offer good efficacy, with over 80% protection against severe RSV-related lower respiratory tract infections in adults over the age of 60. The RSV vaccine showed an overall efficacy of 83% for all RSV infections and 94% for severe infections, while the Renoir trial showed 67% efficacy against lower respiratory infections and 86% efficacy against severe cases. Safety profiles were reassuring, with no signs of severe adverse events. However, due to the small number of cases, the level of confidence in the vaccines preventing hospitalization or saving lives remains limited.
Remember Everything You Learn from Podcasts
Save insights instantly, chat with episodes, and build lasting knowledge - all powered by AI.
